Yahoo Finance

Oruka Therapeutics (ORKA) announced that it has initiated dosing of healthy volunteers in its first clinical trial of ORKA-001, the Company’s novel, subcutaneously administered, half-life extended monoclonal antibody targeting IL-23p19. Pharmacokinetic and safety data from healthy volunteers anticipated in the second half of 2025. On track to initiate a proof-of-concept study in psoriasis in the second half of 2025, with initial efficacy data expected in the second half of 2026. Preclinical data with ORKA-001 demonstrate the potential for once- or twice-yearly dosing, a significant improvement over standard of care

Pick the best stocks and maximize your portfolio:

• Discover top-rated stocks from highly ranked analysts with Analyst Top Stocks!

• Easily identify outperforming stocks and invest smarter with Top Smart Score Stocks

Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>

See Insiders’ Hot Stocks on TipRanks >>

Read More on ORKA:

• Oruka Therapeutics to be added to Nasdaq Biotechnology Index

• Oruka Therapeutics: Strong Q3 and Strategic Advances

• Oruka Therapeutics files to sell 8.72M shares of common stock for holders

• Oruka Therapeutics reports Q3 EPS ($1.46), consensus (40c)